Uday Nagesh Shivaji

Dr. Uday Nagesh Shivaji

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
Uday Nagesh ShivajiUday Nagesh Shivaji
Uday Nagesh Shivaji
CSCaroline L. Sharratt
Caroline L. Sharratt
TTTom Thomas
Tom Thomas
SSSamuel C. L. Smith
Samuel C. L. Smith
Marietta IacucciMarietta Iacucci
Marietta Iacucci
NBNeeraj Bhala
Neeraj Bhala
Summary: Background: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti‐TNF therapies. Biosimilar anti‐TNF monoclonal antibodies are increasingly used. Anti‐TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients. Gastroenterologists need to understand the mechanisms for these effects, recognise these swiftly and manage such events appropriately.Aim: To cover the range of potential adverse reactions as a result of biologic therapy and specifically management of these events.Methods: A Medline and Pubmed search was undertaken. Search terms included were “anti‐TNF,” “infliximab” or “adalimumab” or “golimumab” combined with the keywords “ulcerative colitis” or “Crohn's disease” or “inflammatory bowel disease” and then narrowed to articles containing the keywords “complications,” “side effects” or “adverse events” or “safety profile.” International guidelines were also reviewed where relevant.Results: Adverse events discussed in this review include infusion reactions, blood disorders and infections (including bacterial, viral, fungal and opportunistic infections) as well as autoimmune, dermatological disorders, cardiac and neurological conditions. Malignancies including solid organ, haematological and those linked to viral disease are discussed.Conclusions: Anti‐TNF therapy has wide‐ranging effects on the immune system resulting in a spectrum of potential adverse events in a small proportion of patients. Research advances are improving the understanding, recognition and management of these adverse events.

1 January 2019 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
PDF file
Uday Nagesh ShivajiUday Nagesh Shivaji
Uday Nagesh Shivaji
LJLouisa Jeffery
Louisa Jeffery
XGXianyong Gui
Xianyong Gui
SSSamuel C. L. Smith
Samuel C. L. Smith
OAOmer F. Ahmad
Omer F. Ahmad
Marietta IacucciMarietta Iacucci
Marietta Iacucci
Background: Drug-induced colitis is a known complication of therapies that alter the immune balance, damage the intestinal barrier or disturb intestinal microbiota. Immune checkpoint inhibitors (ICI) directed against cancer cells may result in activated T lymphocyte-induced immune-related adverse events (AEs), including immune-related colitis and hepatitis. The aim of this review article is to summarize the incidence of gastrointestinal (GI) and hepatic AEs related to ICI therapy. We have also looked at the pathogenesis of immune-mediated AEs and propose management strategies based on current available evidence. Methods: A literature search using PubMed and Medline databases was undertaken using relevant search terms pertaining to names of individual drugs, mechanism of action, related AEs and their management. Results: ICI-related GI AEs are common, and colitis appears to be the most common side effect, with some studies reporting incidence as high as 30%. The incidence of both all-grade colitis and hepatitis were highest with combination therapy with anti-CTLA-4/PD-1; severity of colitis was dose-dependent (anti-CTLA-4). Early intervention is associated with better outcomes. Conclusion: ICI-related GI and hepatic AEs are common and clinicians need to be aware. Patients with GI AEs benefit from early diagnosis using endoscopy and computed tomography. Early intervention with oral steroids is effective in the majority of patients, and in steroid-refractory colitis infliximab and vedolizumab have been reported to be useful; mycophenolate has been used for steroid-refractory hepatitis.

15 March 2022 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
SMSnehali Majumder
Snehali Majumder
Uday Nagesh ShivajiUday Nagesh Shivaji
Uday Nagesh Shivaji
RKRangarajan Kasturi
Rangarajan Kasturi
ASAlben Sigamani
Alben Sigamani
SGSubrata Ghosh
Subrata Ghosh
MIMarietta Iacucci
Marietta Iacucci
Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives

21 May 2021 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
Marietta IacucciMarietta Iacucci
Marietta Iacucci
LJLouisa Jeffery
Louisa Jeffery
Animesh AcharjeeAnimesh Acharjee
Animesh Acharjee
ONOlga Maria Nardone
Olga Maria Nardone
DZDavide Zardo
Davide Zardo
SGSubrata Ghosh
Subrata Ghosh
Background: Endoscopic and histological remission are both important treatment goals in patients with ulcerative colitis (UC). We aimed to define cellular architecture, expression of molecular markers, and their correlation with endoscopic scores assessed by ultra-high magnification endocytoscopy (ECS) and histological scores. Methods: Patients with UC (n = 29) were prospectively recruited. The correlation among ECS score (ECSS), Mayo endoscopic score (MES), and histological scores were determined. Area under curve were plotted to determine the best thresholds for ECSS that predicted histological remission by Robarts (RHI) and Nancy Histological Index (NHI). Soluble analytes relevant to inflammation were measured in serum and mucosal culture supernatants using ProcartaPlex Luminex assays and studied by partial least square discriminant analysis and logistic model. Mucosal RNA sequencing and bioinformatics analysis were performed to define differentially expressed genes/pathways. Results: Endocytoscope scoring system correlated strongly with RHI (r = 0.89; 95% CI, 0.51–0.98) and NHI (r = 0.86; 95% CI, 0.42–0.98) but correlated poorly with MES (r = 0.28; 95% CI, 0.27–0.70). We identified soluble brain-derived neurotrophic factors (BDNF), macrophage inflammatory proteins (MIP-1 α) and soluble vascular cell adhesion molecule 1 (sVCAM-1) predicted histological remission. Mucosal biopsy cultures also identified sVCAM-1 associated with healed mucosa. RNA-seq analysis identified gene expressions shared between ECSS, RHI, or NHI defined healing. A number of gene expressions and pathways were identified including inflammation and metabolic and tumor suppressors that discriminated healed from nonhealed mucosa. Conclusions: Endocytoscopy represents an interesting tool that may sit between endoscopy and histology—but closer to the latter—identifying gene expression markers and pathways that are also identified by histology.

2 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSamuel C. L. Smith
Samuel C. L. Smith
CBCarl Banbury
Carl Banbury
DZDavide Zardo
Davide Zardo
RCRosanna Cannatelli
Rosanna Cannatelli
ONOlga Maria Nardone
Olga Maria Nardone
Marietta IacucciMarietta Iacucci
Marietta Iacucci
Background: Mucosal healing (MH) is a key treatment target in the management of inflammatory bowel disease (IBD) and is defined in endoscopic terms by the newly published PICaSSO score. Raman Spectroscopy (RS) is based on the scattering of inelastic light giving spectra that are highly specific for individual molecules. We aimed to establish spectral changes before and after treatment and whether Raman Spectroscopy is able to accurately differentiate between inflammation and MH. Methods: Biopsies were taken for ex vivo RS analysis alongside biopsies for histological analysis from IBD patients undergoing optical diagnosis endoscopic assessment. We compared pre- vs. post-biological treatment in IBD patients and healthy controls and active vs. MH in UC and CD. For spectral analysis, we used supervised self-organising maps for separation and classification. Results: A total of 23 patients (14 IBD, 9 HC) were recruited for comparison of pre- vs. post-biologic treatment and 74 IBD patients were included for the assessment of MH in IBD, giving 9700 Raman Spectra. Spectral differences were seen between pre- and post-treatment which were observed comparing MH vs. active inflammation. Reductions in intensity at 1003cm-1 and 1252cm-1 when a reduction in inflammation was seen post-treatment and when MH was present. MH was associated with an increase in intensity at 1304cm-1. The trained neural network differentiated MH from active inflammation with a sensitivity, specificity, PPV, NPV and accuracy in UC of 96.29% (sd 0.94), 95.03% (sd 1.52), 94.89% (sd 1.59), 96.33 (sd 0.97) and 95.65 (sd 0.99) and 96.19% (sd 1.46), 88% (sd 4.20), 86.60% (sd 5.39), 96.55% (sd 1.32) and 91.6% (sd 2.75) in CD respectively. Conclusion: We demonstrated RS can demonstrate biochemical changes following treatment of IBD and accurately differentiates MH from active inflammation in IBD and might be a future tool to personalise therapeutic management in IBD.

1 January 2024 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Open access
SSSahana Shankar
Sahana Shankar
SMSnehali Majumder
Snehali Majumder
SMSuparna Mukherjee
Suparna Mukherjee
ABAnirban Bhaduri
Anirban Bhaduri
RKRangarajan Kasturi
Rangarajan Kasturi
Uday Nagesh ShivajiUday Nagesh Shivaji
Uday Nagesh Shivaji
The rapid emergence of inflammatory bowel disease (IBD) in Asia in the last two decades is anticipated to pose significant challenges to the healthcare systems of developing countries including India. Several epidemiological factors in the Asia Pacific region have been explored as risk factors for the development of IBD. In this narrative review, we discuss the evolution of adult-onset and paediatric IBD in South Asia and India, in relation to the current global epidemiology, over the last decade. The focus lies on the changing epidemiological landscape of IBD in Asia which signals a paradigm shift in the disease trajectory of a chronic, relapsing, complex disease. We enumerate the disease burden of IBD in India and Asia, analyse the risk factors for its recent rise in incidence and briefly discuss the unique entity of very early-onset IBD. We also list the locoregional challenges in diagnosis and management along with suggestions to overcome them. We highlight the lacunae in data which warrants further research. The anticipated infrastructural challenges and disease evolution are likely to be similar in most newly industrialized countries across South Asia. A combined effort led by IBD experts in the region to understand the true disease burden is important. A strong collaborative network on research and formulation of preventive strategies relevant to the region will help reduce the burden in the future.